Quarterly report · Q2
4583.TEDINET S100S9VE
Period2023-01-01 → 2023-06-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Amends S100RN56.
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥359m | 2023-01-01 → 2023-06-30 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥278m | 2022-01-01 → 2022-06-30 | Standalone | Net sales |
| Operating income | −¥659m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Operating income | −¥779m | 2022-01-01 → 2022-06-30 | Standalone | Operating income |
| Ordinary income | −¥662m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥661m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Income before income taxes |
| Net income | −¥664m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥771m | 2022-01-01 → 2022-06-30 | Standalone | Profit loss |
| Total assets | ¥1.7bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥1.9bn | at 2022-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥541m | at 2023-06-30 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2022-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2023-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2022-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥595m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥660m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥82,000 | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥113m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥341m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-13.7 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9 | 2023-04-01 → 2023-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.17 | 2022-01-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.53 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.2% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.3% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,503,800 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,057,600 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥266m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥602m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥209m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | −¥393m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥239m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥691m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥540m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 444
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)飯作 哲男 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都江東区 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)平田 重一 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)愛媛県松山市 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)山戸 福太郎 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。単元株式数 100株 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYTDDuration | Original text (Japanese)当社は子会社がありませんので、四半期連結財務諸表を作成しておりません。 | |
| Quarterly balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding inventories (text) | CurrentQuarterInstant_NonConsolidatedMember | Text · Plus | |
| Notes regarding research and development expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding other of selling general and administrative expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes financial instruments quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes securities quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |